Details

Autor(en) / Beteiligte

• Shahbazi, Zahra
• Yazdani, Reza
• Shahkarami, Sepideh
• Shahbazi, Shirin
• Hamid, Mohammad
• Sadeghi-Shabestari, Mahnaz
• Momen, Tooba
• Aleyasin, Soheila
• Esmaeilzadeh, Hossein
• Darougar, Sepideh
• Delavari, Sama
• Mahdaviani, Seyed Alireza
• Ahanchian, Hamid
• Behmanesh, Fatemeh
• Kiaee, Fatemeh
• Chavoshzade, Zahra
• Shariat, Mansoureh
• Keramatipour, Mohammad
• Rezaei, Nima
• Abolhassani, Hassan
• Parvaneh, Nima
• Mahdian, Reza
• Aghamohammadi, Asghar

Titel

Genetic mutations and immunological features of severe combined immunodeficiency patients in Iran

Ist Teil von

• Immunology letters, 2019-12, Vol.216, p.70-78

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2019

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• •Detecting genetic defects in a large number of SCID patients.•Molecular diagnosis is a critical step for genetic counseling, carrier detection, and prenatal diagnosis in SCID patients.•Applying rational ways based on immunological and clinical findings can be very effective in managing the disease and reducing costs. Severe combined immunodeficiency (SCID) is the most severe form of primary immunodeficiency disorders that is characterized by impaired early T lymphocyte differentiation and is variably associated with abnormal development of other lymphocyte lineages. SCID can be caused by mutations in more than 20 different genes. Molecular diagnosis in SCID patients contributes to genetic counseling, prenatal diagnosis, treatment modalities, and overall prognosis. In this cohort, the clinical, laboratory and genetic data related to Iranian SCID patients were comprehensively evaluated and efficiency of stepwise sequencing methods approach based on immunophenotype grouping was investigated Clinical and laboratory data from 242 patients with SCID phenotype were evaluated. Molecular genetic analysis methods including Sanger sequencing, targeted gene panel and whole exome sequencing were performed on 62 patients. Mortality rate was 78.9% in the cohort with a median follow-up of four months. The majority of the patients had a phenotype of T-NK-B+ (34.3%) and the most severe clinical manifestation and highest mortality rate were observed in T-NK-B- SCID cases. Genetic mutations were confirmed in 50 patients (80.6%), of which defects in recombination-activating genes (RAG1 and RAG2) were found in 16 patients (32.0%). The lowest level of CD4+ and CD8+ cells were observed in patients with ADA deficiency (p = 0.026) and IL2RG deficiency (p = 0.019), respectively. Current findings suggest that candidate gene approach based on patient's immunophenotype might accelerate molecular diagnosis of SCID patients. Candidate gene selection should be done according to the frequency of disease-causing genes in different populations. Targeted gene panel, WES and WGS methods can be used for the cases which are not diagnosed using this method.